Literature DB >> 31564486

Adherence to consensus guidelines for screening of primary aldosteronism in an urban healthcare system.

Maheshwaran Sivarajah1, Toni Beninato2, Thomas J Fahey3.   

Abstract

BACKGROUND: Primary aldosteronism is a common cause of secondary hypertension. Treatment with adrenalectomy or mineralocorticoid receptor-blockers can prevent long-term adverse outcomes. This study aimed to determine primary aldosteronism screening rats in patients with hypertension in an underserved urban healthcare system.
METHODS: We reviewed records of outpatient adults in an urban healthcare system from 2013 to 2017. Chart review along with International Statistical Classification of Diseases, 9th and 10th editions, diagnosis codes were used to identify patients meeting inclusion criteria for screening according to the 2016 Endocrine Society guidelines. The corresponding aldosterone, plasma renin activity, and 24-hour urine aldosterone values were identified. Multivariate logistic regression was performed to determine positive predictors of screening.
RESULTS: Of 15,511 hypertensive patients seen, 6,809 (43.8%) met criteria for screening. Blacks were the most common racial group, and Medicare and Medicaid were the most frequent insurers. The aldosterone-to-renin ratio level was checked in 86 (1.3%) patients; 22 (25.6%) had an aldosterone-to-renin ratio >20. Of the 77 patients with hypertension and incidentaloma, 14 (18.2%) had an aldosterone-to-renin ratio checked. Additional positive predictors for being screened were hypertension and hypokalemia and sustained hypertension.
CONCLUSION: Screening rates for primary aldosteronism in an underserved population are low. Proper identification of primary aldosteronism in those at risk could help ameliorate long-term effects of disease.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31564486     DOI: 10.1016/j.surg.2019.05.087

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  9 in total

1.  Screening Rate for Primary Aldosteronism Among Patients With Apparent Treatment-Resistant Hypertension: Retrospective Analysis of Current Practice.

Authors:  Kidmealem Zekarias; Katelyn M Tessier
Journal:  Endocr Pract       Date:  2021-11-27       Impact factor: 3.443

2.  Screening Rates for Primary Aldosteronism Among Individuals With Hypertension Plus Hypokalemia: A Population-Based Retrospective Cohort Study.

Authors:  Gregory L Hundemer; Haris Imsirovic; Anand Vaidya; Nicholas Yozamp; Rémi Goupil; François Madore; Mohsen Agharazii; Greg Knoll; Manish M Sood
Journal:  Hypertension       Date:  2021-10-18       Impact factor: 10.190

Review 3.  Primary aldosteronism - a multidimensional syndrome.

Authors:  Adina F Turcu; Jun Yang; Anand Vaidya
Journal:  Nat Rev Endocrinol       Date:  2022-08-31       Impact factor: 47.564

Review 4.  Updates in hypertension: new trials, targets and ways of measuring blood pressure.

Authors:  Liann Abu Salman; Jordana B Cohen
Journal:  Curr Opin Nephrol Hypertens       Date:  2022-03-04       Impact factor: 3.416

5.  Recalibrating Interpretations of Aldosterone Assays Across the Physiologic Range: Immunoassay and Liquid Chromatography-Tandem Mass Spectrometry Measurements Under Multiple Controlled Conditions.

Authors:  Jenifer M Brown; Richard J Auchus; Brooke Honzel; James M Luther; Nicholas Yozamp; Anand Vaidya
Journal:  J Endocr Soc       Date:  2022-03-23

6.  Testing for Primary Aldosteronism and Mineralocorticoid Receptor Antagonist Use Among U.S. Veterans : A Retrospective Cohort Study.

Authors:  Jordana B Cohen; Debbie L Cohen; Daniel S Herman; John T Leppert; James Brian Byrd; Vivek Bhalla
Journal:  Ann Intern Med       Date:  2020-12-29       Impact factor: 25.391

7.  Screening for Primary Aldosteronism is Underutilized in Patients with Obstructive Sleep Apnea.

Authors:  Patricia C Conroy; Sophia Hernandez; Claire E Graves; Kathryn Chomsky-Higgins Menut; Sarah Pearlstein; Chienying Liu; Wen T Shen; Jessica Gosnell; Julie A Sosa; Sanziana Roman; Quan-Yang Duh; Insoo Suh
Journal:  Am J Med       Date:  2021-09-09       Impact factor: 5.928

8.  Screening for primary aldosteronism is underutilised in patients with chronic kidney disease.

Authors:  Karanjeet Chauhan; Eitan Schachna; Renata Libianto; Jessica Ryan; Holly Hutton; Peter J Fuller; Scott Wilson; Peter G Kerr; Jun Yang
Journal:  J Nephrol       Date:  2022-02-23       Impact factor: 4.393

9.  Screening for primary aldosteronism in the hypertensive obstructive sleep apnea population is cost-saving.

Authors:  Kathryn Chomsky-Higgins Menut; Sarah Sims Pearlstein; Patricia C Conroy; Sanziana A Roman; Wen T Shen; Jessica Gosnell; Julie Ann Sosa; Quan-Yang Duh; Insoo Suh
Journal:  Surgery       Date:  2021-07-06       Impact factor: 4.348

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.